Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 9 METERS BIOPHARMA, INC.NMTR · Entity 114271 | Director | July 06, 2020 | July 08, 2020 |
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 13, 2026 |
| Canton Strategic Holdings, Inc.HILS · Entity 6394 | 10% owner | January 11, 2022 | January 12, 2022 |
| Instil Bio, Inc.TIL · Entity 7177 | CFO and CBO | September 10, 2025 | September 12, 2025 |
| Unicycive Therapeutics, Inc.UNCY · Entity 6568 | Director | May 14, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
9 METERS BIOPHARMA, INC.
Report date July 06, 2020 · Filed July 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2030-07-06 | Direct | 150,000 |
Reported balance
After 2020-07-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-06 · Grant · Acquired 150,000 · Balance 150,000 F1: The option shall vest in 36 equal monthly installments beginning July 6, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in 36 equal monthly installments beginning July 6, 2020.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
Canton Strategic Holdings, Inc.
Report date January 11, 2022 · Filed January 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | IndirectSee Footnote | 636,008 |
Reported balance
Holding disclosure · report date 2022-01-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 636,008 F1: Sandeep Laumas is the Managing Member of Bearing Circle Capital LLC and in such capacity has the right to vote and dispose of the securities held by such entity. |
| Convertible NoteSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-01-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: On May 10, 2021, the Registrant issued the Reporting Person a $60,000 note which matures on the earlier of (i) May 10, 2024 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing and shall be equal to the quotient obtained by dividing the outstanding amount of the note by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents. |
| Convertible NoteSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-01-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: On August 4, 2021, the Registrant issued the Reporting Person a Subordinated Convertible Promissory Note (the "August Note") in the principal amount of $40,000. The August Note matures upon the earlier of (i) August 4, 2024 and (ii) the closing of the Next Equity Financing. The principal amount of the August Note together with accrued interest thereon shall automatically convert into the type of Equity Securities issued in the Next Equity Financing. The number of Equity Securities to be issued upon conversion of the August Note shall be equal to the quotient obtained by dividing the outstanding principal amount of the August Note together with interest accrued thereon by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million. |
Filing footnotes · ownership attribution and instrument terms
F1: Sandeep Laumas is the Managing Member of Bearing Circle Capital LLC and in such capacity has the right to vote and dispose of the securities held by such entity.
F2: On May 10, 2021, the Registrant issued the Reporting Person a $60,000 note which matures on the earlier of (i) May 10, 2024 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing and shall be equal to the quotient obtained by dividing the outstanding amount of the note by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents.
F3: On August 4, 2021, the Registrant issued the Reporting Person a Subordinated Convertible Promissory Note (the "August Note") in the principal amount of $40,000. The August Note matures upon the earlier of (i) August 4, 2024 and (ii) the closing of the Next Equity Financing. The principal amount of the August Note together with accrued interest thereon shall automatically convert into the type of Equity Securities issued in the Next Equity Financing. The number of Equity Securities to be issued upon conversion of the August Note shall be equal to the quotient obtained by dividing the outstanding principal amount of the August Note together with interest accrued thereon by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million.
Instil Bio, Inc.
Report date September 10, 2025 · Filed September 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-09-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-09-10 · Exercise / conversion · Acquired 17,000 · Balance 17,000 Row 2 · 2025-09-10 · Exercise / conversion · Acquired 13,000 · Balance 30,000 Row 3 · 2025-09-10 · Sale · Disposed 17,539 · Balance 12,461 F1: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.70 to $23.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Row 4 · 2025-09-10 · Sale · Disposed 12,461 · Balance 0 F2: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $23.71 to $24.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.60 · Expires 2034-02-09 | Direct | 17,000 |
Reported balance
After 2025-09-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-09-10 · Exercise / conversion · Disposed 17,000 · Balance 17,000 F3: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on February 10, 2025 with the remainder vesting in substantially equal monthly tranches thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.68 · Expires 2033-01-07 | Direct | 30,000 |
Reported balance
After 2025-09-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-09-10 · Exercise / conversion · Disposed 13,000 · Balance 30,000 F4: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on January 8, 2024 with the remainder vesting in substantially equal monthly tranches thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.70 to $23.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
F2: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $23.71 to $24.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
F3: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on February 10, 2025 with the remainder vesting in substantially equal monthly tranches thereafter.
F4: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on January 8, 2024 with the remainder vesting in substantially equal monthly tranches thereafter.
Unicycive Therapeutics, Inc.
Report date May 14, 2026 · Filed July 28, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 47,941 |
Reported balance
After 2026-05-14 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 47,941 · Balance 47,941 F1: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 19, 2026 00:57 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 42,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-058662 · ownership.xml · derivative · entry 2 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,300 Underlying: Common Stock · 42,100 shares Expires not disclosed F2 · derivative.exercise_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer. F2 · derivative.expiration_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. The shares subject to the Annual RSU Award shall vest one year after date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed May 19, 2026 00:57 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 84,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-058662 · ownership.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,200 Underlying: Common Stock · 84,200 shares Expires not disclosed F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award vest 1/3 on the anniversary of the grant date for 3 years, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed Jun 15, 2026 21:24 UTC Amendment | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 42,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-068920 · ownership.xml · derivative · entry 2 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,300 Underlying: Common Stock · 42,100 shares Expires not disclosed F2 · derivative.exercise_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. F2 · derivative.expiration_date: Represents grant of restricted stock units (the "Annual RSU Award") payable solely in common stock of the Issuer. 17,542 shares vest upon grant and 3,508 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed Jun 15, 2026 21:24 UTC Amendment | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 84,200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-068920 · ownership.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,200 Underlying: Common Stock · 84,200 shares Expires not disclosed F1 · derivative.exercise_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 11,694 shares vest upon grant and 2,339 vest monthly over 31 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed Jul 28, 2026 20:15 UTC Amendment | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantRestricted Stock Units · Derivative | 47,941 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-082270 · ownership.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,941 Underlying: Common Stock · 47,941 shares Expires not disclosed F1 · derivative.exercise_date: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. F1 · derivative.expiration_date: Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 00:09 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-26-002981 · tm262917-7_4seq1.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 21:00 UTC | Instil Bio, Inc. TIL · Entity 7177 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001789769-25-000087 · wk-form4_1757710851.xml · derivative · entry 6 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 13,000 shares Expires 2033-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on January 8, 2024 with the remainder vesting in substantially equal monthly tranches thereafter. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 21:00 UTC | Instil Bio, Inc. TIL · Entity 7177 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $11.60 | $0.00 |
DisclosureSEC source: 0001789769-25-000087 · wk-form4_1757710851.xml · derivative · entry 5 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Stock option granted under the Instil Bio, Inc. 2021 Incentive Plan. 25% of the shares subject to the option vested on February 10, 2025 with the remainder vesting in substantially equal monthly tranches thereafter. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 21:00 UTC | Instil Bio, Inc. TIL · Entity 7177 | SaleCommon Stock | 12,461 | $23.88 | $297,568.68 |
DisclosureSEC source: 0001789769-25-000087 · wk-form4_1757710851.xml · nonDerivative · entry 4 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $23.71 to $24.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 21:00 UTC | Instil Bio, Inc. TIL · Entity 7177 | SaleCommon Stock | 17,539 | $23.04 | $404,098.56 |
DisclosureSEC source: 0001789769-25-000087 · wk-form4_1757710851.xml · nonDerivative · entry 3 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,461 F1 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $22.70 to $23.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 21:00 UTC | Instil Bio, Inc. TIL · Entity 7177 | Exercise / conversionCommon Stock | 13,000 | $12.68 | $164,840.00 |
DisclosureSEC source: 0001789769-25-000087 · wk-form4_1757710851.xml · nonDerivative · entry 2 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 21:00 UTC | Instil Bio, Inc. TIL · Entity 7177 | Exercise / conversionCommon Stock | 17,000 | $11.60 | $197,200.00 |
DisclosureSEC source: 0001789769-25-000087 · wk-form4_1757710851.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:30 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 21,200 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001213900-25-069305 · ownership.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,286 Underlying: Common Stock · 21,200 shares Expires 2035-07-28 Read SEC document |
| April 25, 2025 Filed Apr 28, 2025 21:00 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 44,851 | $0.00 Strike: $12.78 | $0.00 |
DisclosureSEC source: 0001789769-25-000041 · wk-form4_1745874035.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,851 Underlying: Common Stock · 44,851 shares Expires 2035-04-24 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on April 25, 2026, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| September 18, 2024 Filed Sep 23, 2024 17:12 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $66.10 | $0.00 |
DisclosureSEC source: 0001789769-24-000095 · wk-form4_1727111515.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-09-17 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on September 18, 2025, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 23:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001104659-24-070517 · tm2416928-4_4seq1.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:40 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $11.60 | $0.00 |
DisclosureSEC source: 0001789769-24-000025 · wk-form4_1707863993.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-02-09 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on February 10, 2025, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 20:34 UTC | Unicycive Therapeutics, Inc. UNCY · Entity 6568 | GrantStock Options · Derivative | 189,236 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001213900-23-075014 · ownership.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,864 Underlying: Common Stock · 189,236 shares Expires 2033-09-05 F1 · derivative.exercise_date: 63,079 options vest on June 26, 2024, 63,079 options vest on June 26, 2025 and 63,078 vest on June 26, 2026. Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 20:58 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $17.52 | $0.00 |
DisclosureSEC source: 0001104659-23-075866 · tm2319786-5_4seq1.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| January 08, 2023 Filed Jan 20, 2023 21:08 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 415,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001789769-23-000008 · wf-form4_167424886036425.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,000 Underlying: Common Stock · 415,000 shares Expires 2033-01-07 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on January 8, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 19, 2022 Filed May 23, 2022 22:48 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0001104659-22-063970 · tm2216669-1_4seq1.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-05-19 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 22:06 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 234,000 | $8.62 Strike: $8.62 | $2,017,080.00 |
DisclosureSEC source: 0001789769-22-000013 · wf-form4_164669078591142.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,000 Underlying: Common Stock · 234,000 shares Expires 2032-03-03 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 4, 2023, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 04, 2022 Filed Jan 20, 2023 21:10 UTC Amendment | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 234,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001789769-23-000012 · wf-form4a_167424903416782.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,000 Underlying: Common Stock · 234,000 shares Expires 2032-03-03 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 4, 2023, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:34 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001104659-21-081589 · tm2119762-4_4seq1.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2031-06-11 F1 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 11, 2021 Filed May 13, 2021 20:48 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $16.25 | $0.00 |
DisclosureSEC source: 0001789769-21-000032 · wf-form4_162093887102104.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-05-10 F1 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments commencing on June 11, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 18, 2021 Filed Mar 23, 2021 00:53 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantEmployee Stock Option (right to buy) · Derivative | 240,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-21-022474 · doc4.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments commencing on March 19, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 16:30 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001551986-20-000224 · wf-form4_159424021243087.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2030-07-06 F1 · derivative.exercise_date: The option shall vest in 36 equal monthly installments beginning July 6, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:28 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | ConversionSeries A Convertible Preferred Stock · Derivative | 424 | $0.00 | $0.00 |
DisclosureSEC source: 0001551986-20-000208 · wf-form4_159372161414654.xml · derivative · entry 3 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 42,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock automatically converted to common stock on a 1-to-100 basis upon approval by the Company's stockholders on June 30, 2020. F2 · derivative.expiration_date: The Series A Convertible Preferred Stock automatically converted to common stock on a 1-to-100 basis upon approval by the Company's stockholders on June 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 16:28 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | ConversionCommon stock | 42,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001551986-20-000208 · wf-form4_159372161414654.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:17 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001104659-20-065876 · a4.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-21 F1 · derivative.exercise_date: The option will vest in full and become exercisable on the earlier of the first anniversary of the grant date or the day immediately prior to the date of the next BioXcel Therapeutics, Inc. annual meeting of stockholders, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 04, 2020 Filed May 4, 2020 18:47 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | PurchaseSeries A Convertible Preferred Warrant · Derivative | 424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001551986-20-000116 · wf-form4_158863244260467.xml · derivative · entry 2 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,400 Underlying: Common stock · 42,400 shares Expires 2025-05-04 F2 · derivative.exercise_price: The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis. F2 · price: The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis. Read SEC document |
| May 04, 2020 Filed May 4, 2020 18:47 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | PurchaseSeries A Convertible Preferred Stock · Derivative | 424 | $0.00 | $0.00 |
DisclosureSEC source: 0001551986-20-000116 · wf-form4_158863244260467.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,400 Underlying: Common stock · 42,400 shares Expires not disclosed F1 · derivative.exercise_price: The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date. F1 · derivative.expiration_date: The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date. Read SEC document |
| April 24, 2020 Filed May 4, 2020 18:02 UTC | 9 METERS BIOPHARMA, INC. NMTR · Entity 114271 | GrantStock Option (Right to Buy) · Derivative | 389,294 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001551986-20-000108 · wf-form4_158862973478780.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,294 Underlying: Common stock · 389,294 shares Expires 2030-04-24 F1 · derivative.exercise_date: The option vested in full on 4/24/2020. Read SEC document |
| August 20, 2019 Filed Aug 27, 2019 18:41 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001551986-19-000107 · wf-form4_156694565180767.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · CEO, Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common stock · 400,000 shares Expires 2029-02-18 F1 · derivative.exercise_date: 25% of these shares shall be deemed vested and exercisable on February 19, 2019 with the remainder vesting monthly over the next 48 months, subject to the executive's continuous service with the Company through each applicable vesting date. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 17:00 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 4,000 | $1.15 | $4,600.00 |
DisclosureSEC source: 0001551986-19-000082 · wf-form4_156201478728094.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · CEO, Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.1477 to $1.1500, inclusive. The reporting person undertakes to provide to Innovate Biopharmaceuticals, Inc., any security holder of Innovate Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:03 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 591 | $1.22 | $721.02 |
DisclosureSEC source: 0001551986-19-000077 · wf-form4_156081619312014.xml · nonDerivative · entry 2 Laumas Sandeep · CIK 0001721664 · Director · CEO, Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:03 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 409 | $1.21 | $494.89 |
DisclosureSEC source: 0001551986-19-000077 · wf-form4_156081619312014.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · CEO, Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,409 Read SEC document |
| May 23, 2019 Filed May 29, 2019 01:01 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 14,700 | $0.00 Strike: $10.04 | $0.00 |
DisclosureSEC source: 0001104659-19-032143 · a4.xml · derivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,700 Underlying: Common Stock · 14,700 shares Expires 2029-05-23 F1 · derivative.exercise_date: The option will vest in full and become exercisable on the first anniversary of the grant date. Read SEC document |
| May 22, 2019 Filed May 23, 2019 08:44 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 5,000 | $1.38 | $6,900.00 |
DisclosureSEC source: 0001551986-19-000054 · wf-form4_155861548321435.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · CEO, Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 19:16 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 1,000 | $2.63 | $2,630.00 |
DisclosureSEC source: 0001551986-18-000060 · wf-form4_154388259801782.xml · nonDerivative · entry 3 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 19:16 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 1,000 | $2.62 | $2,620.00 |
DisclosureSEC source: 0001551986-18-000060 · wf-form4_154388259801782.xml · nonDerivative · entry 2 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 19:16 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 1,000 | $2.64 | $2,640.00 |
DisclosureSEC source: 0001551986-18-000060 · wf-form4_154388259801782.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| November 29, 2018 Filed Nov 29, 2018 18:13 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 2,000 | $2.56 | $5,120.00 |
DisclosureSEC source: 0001551986-18-000055 · wf-form4_154353318919549.xml · nonDerivative · entry 2 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| November 29, 2018 Filed Nov 29, 2018 18:13 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 1,000 | $2.55 | $2,550.00 |
DisclosureSEC source: 0001551986-18-000055 · wf-form4_154353318919549.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 17:49 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 500 | $6.10 | $3,050.00 |
DisclosureSEC source: 0001551986-18-000029 · wf-form4_153661614405437.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · balance_after: Due to an administrative error, the holdings reported on Dr. Laumas's prior Form 4 filing were understated by 750 shares. This balance now reflects the correct amount of Dr. Laumas's direct holdings. Read SEC document |
| August 30, 2018 Filed Aug 30, 2018 20:41 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 500 | $5.24 | $2,620.00 |
DisclosureSEC source: 0001551986-18-000027 · wf-form4_153567608554397.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.24 to $5.25, inclusive. The reporting person undertakes to provide to Innovate Biopharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| August 28, 2018 Filed Aug 28, 2018 18:17 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 405 | $5.08 | $2,057.40 |
DisclosureSEC source: 0001551986-18-000020 · wf-form4_153549465706467.xml · nonDerivative · entry 4 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| August 28, 2018 Filed Aug 28, 2018 18:17 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 95 | $5.07 | $481.65 |
DisclosureSEC source: 0001551986-18-000020 · wf-form4_153549465706467.xml · nonDerivative · entry 3 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595 Read SEC document |
| August 28, 2018 Filed Aug 28, 2018 18:17 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 250 | $4.88 | $1,220.00 |
DisclosureSEC source: 0001551986-18-000020 · wf-form4_153549465706467.xml · nonDerivative · entry 2 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| August 28, 2018 Filed Aug 28, 2018 18:17 UTC | 9 METERS BIOPHARMA, INC. INNT · Entity 114271 | PurchaseCommon stock | 0 | $4.90 | $0.00 |
DisclosureSEC source: 0001551986-18-000020 · wf-form4_153549465706467.xml · nonDerivative · entry 1 Laumas Sandeep · CIK 0001721664 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.